Key facts
- This page summarizes Jack A. Khattar's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 08 Aug 2025, 16:40.
Jack A. Khattar - 06 Aug 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Reporting relationship
- President, CEO, Director
- Issuer ticker
- SUPN
- Reported as of
- 06 Aug 2025
- Net transaction value
- -$2,270,135
- SEC form
- 4
- Accepted by SEC
- 08 Aug 2025, 16:40:02 UTC
- Prior SEC filing
- 23 Jun 2025
- Next SEC filing
- 26 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jack A. Khattar filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 08 Aug 2025.
Change
- Previous filing in this sequence was filed on 23 Jun 2025.
- Current net transaction value: -$2,270,135.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001539937
Primary reporting owner
Khattar Jack A.
- Relationship
- President, CEO, Director
- Address
- C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE
- Signature
- /s/ Timothy C. Dec, as attorney-in-fact
- Signature date
- 08 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- $778,800
- Shares
- +60,000
- Change %
- +5.9%
- Price
- $12.98
- Shares after
- 1,068,683
- Date
- 06 Aug 2025
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Sale
- Transaction value
- $1,549,240
- Shares
- -38,500
- Change %
- -3.6%
- Price
- $40.24
- Shares after
- 1,030,183
- Date
- 06 Aug 2025
- Ownership
- Direct
- Footnotes
- F2
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- $778,800
- Shares
- +60,000
- Change %
- +5.8%
- Price
- $12.98
- Shares after
- 1,090,183
- Date
- 06 Aug 2025
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Sale
- Transaction value
- $1,596,000
- Shares
- -38,000
- Change %
- -3.5%
- Price
- $42.00
- Shares after
- 1,052,183
- Date
- 06 Aug 2025
- Ownership
- Direct
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- $2,055,625
- Shares
- +81,250
- Change %
- +7.7%
- Price
- $25.30
- Shares after
- 1,133,433
- Date
- 06 Aug 2025
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Sale
- Transaction value
- $2,738,120
- Shares
- -63,500
- Change %
- -5.6%
- Price
- $43.12
- Shares after
- 1,069,933
- Date
- 06 Aug 2025
- Ownership
- Direct
- Footnotes
- F3
SUPN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,005,600
- Date
- 06 Aug 2025
- Ownership
- By the KBT Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -60,000
- Change %
- -24%
- Price
- $0.000000
- Shares after
- 195,000
- Date
- 06 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $12.98
- Footnotes
- F4
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -60,000
- Change %
- -31%
- Price
- $0.000000
- Shares after
- 135,000
- Date
- 06 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $12.98
- Footnotes
- F4
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -81,250
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 243,750
- Date
- 06 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 81,250
- Exercise price
- $25.30
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.70. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Footnote F4
The option vested in four equal installments beginning on March 1, 2017.
Footnote F5
The option vests in four equal installments beginning on February 24, 2018